Seres Therapeutics
MCRB
94 hedge funds and large institutions have $382M invested in Seres Therapeutics in 2016 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 39 increasing their positions, 17 reducing their positions, and 20 closing their positions.
129% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 17
20% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 20
3% more funds holding
Funds holding: 91 → 94 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
58% less capital invested
Capital invested by funds: $916M → $382M (-$534M)
73% less call options, than puts
Call options by funds: $713K | Put options by funds: $2.61M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$17.3M |
| 2 |
D.E. Shaw & Co
New York
|
+$9.05M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$5.85M |
| 4 |
Renaissance Technologies
New York
|
+$5.2M |
| 5 |
AG
Artal Group
Luxembourg
|
+$3.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$19.5M |
| 2 |
BM
Bridger Management
New York
|
-$18.1M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
-$14.3M |
| 4 |
CCI
Columbus Circle Investors
|
-$10.7M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$7.35M |
MCRB Hedge Fund Activity: Q3 2016 in Review
94 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q3 2016, worth a combined $382M — down 58% from $916M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new MCRB positions and 20 closed out — a net gain of 4 holders — while 39 added to existing stakes and 17 trimmed.
The largest buyer was Capital World Investors, adding an estimated $17.3M. The largest seller was Jennison Associates, exiting entirely with an estimated $19.5M sold.
- 94 institutional investors held Seres Therapeutics (MCRB) as of Q3 2016, up from 91 in Q2 2016.
- Funds reported $382M of Seres Therapeutics stock for Q3 2016, down 58% quarter-over-quarter.
- 24 funds opened new Seres Therapeutics positions in Q3 2016 and 20 closed out, a net change of +4 holders.
- The largest Seres Therapeutics buyer in Q3 2016 was Capital World Investors, an estimated $17.3M added.
- The largest Seres Therapeutics seller in Q3 2016 was Jennison Associates, an estimated $19.5M sold.
Based on aggregated 13F filings for Q3 2016.